Aspira Pathlab & Diagnostics Board Approves ₹65 Crore Rights Issue

Board approved fundraise of up to Rs 65 Cr via rights issue to eligible shareholders as on record date, via equity or convertible instruments, subject to approvals. Formed Rights Issue Committee. First dilution after years with unchanged capital; size dwarfs revenue and cash scale. Revives fundraise deferred at prior board; terms left to promoter-led committee. Price, entitlement ratio, record date, instrument and use of proceeds undisclosed; needs shareholder and regulatory nods. Implies heavy dilution overhang until terms set.